Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement

Kalra S., Latif Z., ÇÖMLEKÇİ A., Galvez G., Malik R., Pathan M., ...More

Indian Journal of Endocrinology and Metabolism, vol.20, no.4, pp.542-545, 2016 (Scopus) identifier identifier

  • Publication Type: Article / Review
  • Volume: 20 Issue: 4
  • Publication Date: 2016
  • Doi Number: 10.4103/2230-8210.182980
  • Journal Name: Indian Journal of Endocrinology and Metabolism
  • Journal Indexes: Scopus
  • Page Numbers: pp.542-545
  • Keywords: basal insulin, Basal-bolus, coformulation, flexibility, hypoglycemia, insulin, insulin aspart, insulin degludec, insulin degludec/insulin aspart, premixed insulin
  • Dokuz Eylül University Affiliated: Yes


Insulin degludec/insulin aspart (IDegAsp) is a modern coformulation of ultra-long-acting basal insulin degludec, with rapid-acting insulin aspart. IDegAsp provides effective, safe, well-tolerated glycemic control, with a low risk of hypoglycemia while allowing flexibility in meal patterns and timing of administration. This consensus statement describes a pragmatic framework to identify patients who may benefit from IDegAsp therapy. It highlights the utility of IDegAsp in type 2 diabetic patients who are insulin-naive, suboptimally controlled on basal or premixed insulin, or dissatisfied with basal-bolus regimens. It also describes potential IDegAsp usage in type 1 diabetic patients.